#VisualAbstract: Camrelizumab plus gemcitabine and cisplatin improves progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in JAMA Otolaryngology Head & Neck Surgery.
Click to read the study in Nature Communications.
Click to read the study in JAMA Network Open.
1. Adjuvant capecitabine resulted in fewer instances of disease recurrence and death compared to standard therapy. 2. Overall and failure-free ...
Click to read the study in the European Journal of Cancer.
Click to read the study in the Journal of Clinical Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in the Journal of Clinical Oncology.
Click to read the study in JAMA Network Open.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.